for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chiasma Inc

CHMA.OQ

Latest Trade

5.03USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.12

 - 

9.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Chiasma Posts Q3 Loss Per Share Of $0.20

Nov 5 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA REPORTS THIRD QUARTER 2019 RESULTS.Q3 LOSS PER SHARE $0.20.Q3 EARNINGS PER SHARE ESTIMATE $-0.21 -- REFINITIV IBES DATA.CHIASMA OPTIMAL TRIAL, CONDUCTED UNDER SPA AND DESIGNED TO SUPPORT FDA APPROVAL, MET PRIMARY AND ALL SECONDARY ENDPOINTS.MYCAPSSA® NDA ON TRACK FOR SUBMISSION BY YEAR-END 2019.MPOWERED(TM) PHASE 3 TRIAL, DESIGNED TO SUPPORT EU APPROVAL, PROGRESSING AS PLANNED WITH TOPLINE DATA EXPECTED IN 2H 2020.

Chiasma Files For Mixed Shelf Of Up To $200 Million

Sept 6 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.

Chiasma Reports Q2 Loss Per Share $0.25

Aug 8 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA REPORTS SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.25.Q2 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.

Chiasma Announces Proposed Offering Of Common Stock

July 25 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.CHIASMA INC - INTENDS TO USE NET PROCEEDS FROM OFFERING PRIMARILY FOR COMMERCIALIZATION OF MYCAPSSA IN UNITED STATES, IF APPROVED.

Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa For The Maintenance Treatment Of Adults With Acromegaly

July 23 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA ANNOUNCES POSITIVE PHASE 3 TOP-LINE RESULTS FROM CHIASMA OPTIMAL CLINICAL TRIAL OF MYCAPSSA® FOR THE MAINTENANCE TREATMENT OF ADULTS WITH ACROMEGALY.CHIASMA INC - NO NEW OR UNEXPECTED SAFETY SIGNALS IN MYCAPSSA TREATED PATIENTS.CHIASMA INC - NO NEW OR UNEXPECTED SAFETY SIGNALS IN MYCAPSSA TREATED PATIENTS.CHIASMA INC - SPA-AGREED TRIAL MET PRIMARY AND ALL SECONDARY ENDPOINTS.CHIASMA INC - 90% OF PATIENTS TREATED WITH MYCAPSSA WHO COMPLETED 36-WEEK STUDY OPTED TO CONTINUE INTO OPEN LABEL EXTENSION.CHIASMA INC - SPA-AGREED TRIAL MET PRIMARY AND ALL SECONDARY ENDPOINTS.CHIASMA INC - IN CHIASMA OPTIMAL TRIAL, OCTREOTIDE CAPSULES APPEARED SAFE AND WELL TOLERATED.CHIASMA - PLANS TO SUBMIT NDA BY END OF YEAR FOR OCTREOTIDE CAPSULES FOR MAINTENANCE TREATMENT OF ADULTS WITH ACROMEGALY.CHIASMA INC - ENDED JUNE 30, 2019 WITH APPROXIMATELY $58.1 MILLION IN CASH AND INVESTMENTS AS COMPARED TO $41.7 MILLION AT DECEMBER 31, 2018..

Chiasma Strengthens Leadership Team Ahead Of Anticipated Commercial Availability Of Mycapssa

June 5 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA STRENGTHENS LEADERSHIP TEAM AHEAD OF ANTICIPATED COMMERCIAL AVAILABILITY OF MYCAPSSA®.CHIASMA INC - APPOINTS PHARMA COMMERCIAL VETERAN RAJ KANNAN AS CHIEF EXECUTIVE OFFICER.CHIASMA INC - CURRENT CEO MARK FITZPATRICK TO RETAIN ROLE OF PRESIDENT.CHIASMA INC - MANAGEMENT TRANSITION IS EXPECTED TO BE EFFECTIVE NO LATER THAN JUNE 17, 2019..

Chiasma Q1 Loss Per Share $0.36

May 9 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA REPORTS FIRST QUARTER 2019 RESULTS.Q1 LOSS PER SHARE $0.36.Q1 EARNINGS PER SHARE ESTIMATE $-0.34 -- REFINITIV IBES DATA.ADVANCING ITS ONGOING MULTI-NATIONAL MPOWERED™ PHASE 3 TRIAL.ENDED QUARTER WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $33.9 MILLION.

Vivo Opportunity Llc Reports 5.8 Pct Passive Stake In Chiasma Inc As Of April 2

April 12 (Reuters) - Chiasma Inc <CHMA.O>::VIVO OPPORTUNITY LLC REPORTS 5.8 PERCENT PASSIVE STAKE IN CHIASMA INC AS OF APRIL 2 - SEC FILING.

Chiasma Announces Proposed Offering Of Common Stock

March 28 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.

Chiasma Reports Q4 Loss Per Share $0.32

March 8 (Reuters) - Chiasma Inc <CHMA.O>::CHIASMA REPORTS FOURTH QUARTER AND YEAR END 2018 RESULTS.Q4 LOSS PER SHARE $0.32.Q4 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.ASSUMING POSITIVE OPTIMAL DATA, NDA SUBMISSION EXPECTED BY YEAR-END 2019.CHIASMA - ANTICIPATES CURRENT CASH BALANCE SUFFICIENT TO FUND OPERATIONS AS PLANNED THROUGH RELEASE OF CHIASMA OPTIMAL TOP-LINE DATA, INTO EARLY 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up